Influence of a two-year steroid treatment on body composition as measured by dual X-ray absorptiometry in boys with Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 24, Issue 6, 2014, Pages 467-473

  Vuillerot, Carole ^a,b,c,d   Braillon, Pierre ^a   Fontaine Carbonnel, Stephanie ^a   Rippert, Pascal ^a   André, Elisabeth ^e   Iwaz, Jean ^a,b,c   Poirot, Isabelle ^a   Bérard, Carole ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^e Centre Hospitalier d'Arles   (France)

Author keywords

Body composition; Duchenne muscular dystrophy; Steroids

Indexed keywords

PREDNISONE; STEROID;

ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; FAT MASS; HUMAN; LEAN BODY WEIGHT; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; DRUG EFFECTS; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; PHOTON ABSORPTIOMETRY; PRESCHOOL CHILD; RADIOGRAPHY;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; BODY COMPOSITION; CHILD; CHILD, PRESCHOOL; HUMANS; MALE; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; STEROIDS;

EID: 84901036995     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.03.002     Document Type: Article

References (31)

1. Jones D.A., Round J.M., Edwards R.H., Grindwood S.R., Tofts P.S. Size and composition of the calf and quadriceps muscles in Duchenne muscular dystrophy. A tomographic and histochemical study. J Neurol Sci 1983, 60:307-322.
2. Liu G.C., Jong Y.J., Chiang C.H., Jaw T.S. Duchenne muscular dystrophy: MR grading system with functional correlation. Radiology 1993, 186:475-480.
3. Leroy-Willig A., Willig T.N., Henry-Feugeas M.C., et al. Body composition determined with MR in patients with Duchenne muscular dystrophy, spinal muscular atrophy, and normal subjects. Magn Reson Imaging 1997, 15:737-744.
4. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989, 320:1592-1597.
5. Biggar W.D., Harris V.A., Eliasoph L., Alman B. Long-term benefits of Deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006, 16:249-255.
6. Manzur A.Y., Kuntzer T., Pike M., Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, (1). CD003725.
7. Moxley R.T., Pandya S., Ciafaloni E., Fox D.J., Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010, 25:1116-1129.
8. Griggs R.C., Moxley R.T., Mendell J.R., et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18months) and azathioprine (12months). Neurology 1993, 43:520-527.
9. Campbell C., Jacob P. Deflazacort for the treatment of Duchenne dystrophy: a systematic review. BMC Neurol 2003, 3:7-17.
10. Moxley R.T., Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005, 64:13-20.
11. Braillon P.M., Cochat P. Analysis of dual energy X-ray absorptiometry whole body results in children, adolescents and young adults. Appl Radiat Isot 1998, 49:623-624.
12. El Haggan W., Hurault de Ligny B., Partiu A., et al. The evolution of weight and body composition in renal transplant recipients: two-year longitudinal study. Transplant Proc 2006, 38:3517-3519.
13. Engvall I.L., Brismar K., Hafström I., Tengstrand B. Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in Rheumatoid arthritis patients: a controlled cross-sectional study. Scand J Rheumatol 2011, 40:161-168.
14. Rifai Z., Welle S., Moxley R.T., Lorenson M., Griggs R.C. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 1995, 268(1 Pt 1):E67-E74.
15. Palmieri G.M., Bertorini T.E., Griffin J.W., Igarashi M., Karas J.G. Assessment of whole body composition with dual energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function. Muscle Nerve 1996, 19:777-779.
16. Skalsky A.J., Han J.J., Abresch R.T., Shin C.S., McDonald C.M. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength. Muscle Nerve 2009, 39:647-651.
17. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93. DMD Care Considerations Working Group.
18. Shorr I.J. How to weigh and measure children 1986, UN, New York.
19. Gauld L.M., Kappers J., Carlin J.B., Robertson C.F. Height prediction from ulna length. Dev Med Child Neurol 2004, 46:475-480.
20. Bérard C., Payan C., Hodgkinson I., Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 2005, 15:463-470. MFM Collaborative Study Group.
21. Vuillerot C., Girardot F., Payan C., et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the motor function measure. Dev Med Child Neurol 2010, 52:60-65.
22. Braillon PM. Cross-calibration of dual energy X-ray absorptiometry systems with a new anthropomrorphic whole body phantom. Radiological Society of North America meeting, Chicago IL, Nov 2007 Abstract ID: Musculoskeletal - 5011569.
23. Kinali M., Mercuri E., Main M., Muntoni F., Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 2002, 12:169-174.
24. Mok E., Letellier G., Cuisset J.M., Denjean A., Gottrand F., Hankard R. Assessing change in body composition in children with Duchenne muscular dystrophy: anthropometry and bioelectrical impedance analysis versus dual-energy X-ray absorptiometry. Clin Nutr 2010, 29:633-638.
25. Constantinides C.D., Gillen J.S., Boada F.E., Pomper M.G., Bottomley P.A. Human skeletal muscle: sodium MR imaging and quantification-potential applications in exercise and disease. Radiology 2000, 216:559-568.
26. Douvillez B., Braillon P., Hodgkinson I., Berard C. Pain, osteopenia and body composition of 22 patients with Duchenne muscular dystrophy: a descriptive study. Ann Readapt Med Phys 2005, 48:616-622.
27. Finanger E.L., Russman B., Forbes S.C., Rooney W.D., Walter G.A., Vandenborne K. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 2012, 23:1-10.
28. Akima H., Lott D., Senesac C., et al. Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2012, 22:16-25.
29. Arpan I., Forbes S.C., Lott D.J., et al. T mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy. NMR Biomed 2013, 26:320-328.
30. Edmonds C.J., Smith T., Griffiths R.D., Mackenzie J., Edwards R.H. Total body potassium and water, and exchangeable sodium, in muscular dystrophy. Clin Sci 1985, 68:379-385.
31. Lee S.Y., Gallagher D. Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care 2008, 11:566-572.